🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Mitapivat tablet

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  2. Mitapivat tablets

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  3. Nivolumab

    Iovance Biotherapeutics B.V.

    Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  4. Nivolumab

    Iovance Biotherapeutics B.V.

    Melanoma (Skin)

    phase 1 small molecule completed

    1 trial

  5. Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

    Bioprojet Pharma

    Binge eating disorder

    phase 1 other active

    1 trial

  6. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy

    phase 1 small molecule completed

    1 trial

  7. PNEUMOSTEM®

    Samsung Bioepis NL B.V.

    Pulmonary Arterial Hypertension (PAH)

    phase 1 mab active

    1 trial

  8. Pacing Lead

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 1 other completed

    1 trial

  9. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 1 small molecule terminated

    1 trial

  10. Placebo

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 1 small molecule completed

    1 trial

  11. Placebo

    Mirum Pharmaceuticals International B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. Placebo for Treatment A

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. Pozelimab

    Alnylam Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  14. RM-493

    Rhythm Pharmaceuticals Netherlands B.V.

    Overweight

    phase 1 small molecule completed

    1 trial

  15. RP-A601

    Rocket Pharmaceuticals B.V.

    PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

    phase 1 gene therapy active

    1 trial

  16. RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

    Rocket Pharmaceuticals B.V.

    Dilated Cardiomyopathy (DCM)

    phase 1 gene therapy active

    1 trial

  17. RP-L401

    Rocket Pharmaceuticals B.V.

    Infantile Malignant Osteopetrosis

    phase 1 mab terminated

    1 trial

  18. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Renal Insufficiency

    phase 1 small molecule completed

    1 trial

  19. Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  20. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  21. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  22. Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

    Hutchmed Europe B.V.

    Primary immune thrombocytopenia (ITP)

    phase 1 other active

    1 trial

  23. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  24. TIL

    Iovance Biotherapeutics B.V.

    Sarcoma

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources